Sector ratings Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE Other stock markets 21:00:00 10/07/2026 BST			5-day change	1st Jan Change
3.010 ^USD	-5.05%		-17.08%	+9.45%

07-08	Perspective Therapeutics, Inc. Announces Executive Changes	CI
07-08	Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PERSPECTIVE THERAPEUTICS, INC.	343M	-	BBB	-	-
LONZA GROUP AG	50.73B		AAA
REVOLUTION MEDICINES, INC.	39.73B	-	B	-	-
IQVIA HOLDINGS INC.	34.69B		AAA
BEONE MEDICINES AG	33.21B		-
CELLTRION, INC.	26.76B		A
ASCENDIS PHARMA A/S	16.8B	-	-	-	-
MEDPACE HOLDINGS, INC.	15.37B		BBB
EUROFINS SCIENTIFIC SE	13.78B		AA
ICON PUBLIC LIMITED COMPANY	12.85B		AAA
ABIVAX	12.11B	-	BBB	-	-
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	11.24B		AA
BIO-TECHNE CORPORATION	11.11B		AA
TEMPUS AI, INC.	10.46B		A		-
APOGEE THERAPEUTICS, INC.	10.02B	-	B	-	-
KYMERA THERAPEUTICS, INC.	9.82B	-	BBB	-	-
IONIS PHARMACEUTICALS, INC.	9.63B	-	A	-	-
PRAXIS PRECISION MEDICINES, INC.	9.06B	-	B	-	-
ALKERMES PLC	8.66B		A
QIAGEN N.V.	8.58B		AAA
Average	17.25B		A
Weighted average by Cap.			A